What is Macrolide Antibiotics Market?
Macrolide antibiotics are a particular type of antibiotic that inhibits the growth of bacteria by preventing them from being able to produce proteins that are essential for their growth. These antibiotics used to treat, and sometimes prevent, a wide variety of bacterial infections. Macrolide antibiotics are azithromycin, clarithromycin, erythromycin, spiramycin, and telithromycin. These antibiotics are only effective in treating bacterial infections associated with conditions such as ear, nose, and throat infections, chest infections, skin infections, sexually transmitted diseases, mouth, and dental infections. Macrolide antibiotics may be prescribed to prevent a certain type of bacterial infection and can be used as an alternative to penicillin antibiotics.
The market study is being classified by Type (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), by Application (Ear, Nose and Throat Infections, Chest Infections, Skin Infections, Mouth and Dental Infections and Sexually Transmitted Infections) and major geographies with country level break-up.
Macrolide Pharmaceuticals (United States), Teva Pharmaceutical Industries Ltd. (Israel), Merck Sharp & Dohme Corp (United States), Pfizer Inc. (United States), Aurobindo Pharma Limited (India), Neo Química (Brazil), Fresenius Kabi USA (United States), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (United States) and WOCKHARDT (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Alembic Pharmaceuticals Ltd (India), Bionpharma Inc. (United States) and Novartis International AG (Switzerland).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Macrolide Antibiotics market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Macrolide Antibiotics market by Type, Application and Region.
On the basis of geography, the market of Macrolide Antibiotics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Bacterial Infections
- Rise in the Number of Hospitals and Clinics
- Increased Research and Development Investments
- Side Effects of the Macrolide Antibiotics
- Growth in the Healthcare Industry
- Huge Investments by Major Players in the Market
- Stringent Government Rules and Regulations
In January 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the availability of a generic version of NuvaRing (etonogestrel and Ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
Key Target AudienceMacrolide Antibiotics Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase